title: [Role of the Immune System and Possibilities of Immunotherapy in Prostate Cancer].
abstract: In recent years, thanks to new advances in tumor immunology, immunotherapy became a part of intensive research as a novel strategy in cancer treatment. Sipuleucel T is the first and only medicinal product approved by the regulatory agencies in the USA and Europe for the treatment of asymptomatic or minimal symptomatic castrate re-fractory prostate cancer. It represents the first product of autologous cell therapy. This article gives a brief overview of new approaches in cancer immunotherapy in clinical development.
authors.forename: K
authors.initials: K
authors.lastname: Kubáčková
mesh_terms: D019496:Cancer Vaccines / Q000627:therapeutic use*; D006801:Humans; D007107:Immune System / Q000502:physiology*; D008297:Male; D011471:Prostatic Neoplasms / Q000276:immunology / Q000628:therapy*; D014020:Tissue Extracts / Q000627:therapeutic use*
chemical_list: D019496:Cancer Vaccines; D014020:Tissue Extracts; C511774:sipuleucel-T